Login to Access Video or Poster Abstract: MP56-02
Sources of Funding: None

Introduction

To examine the efficacy and safety of collagenase Clostridium histolyticum (CCH) in the treatment of acute phase Peyronie's Disease (PD).

Methods

We conducted a retrospective review of the records for all patients treated with CCH for PD between 04/2014 and 03/2016. Patients qualified as being in the acute phase of PD if they reported penile pain and duration of PD < 12 months at presentation. The primary outcomes of interest were final change in curvature after CCH treatment regardless of number of CCH cycles received, and frequency of treatment-related adverse events (TRAE). Paired t-Test and Chi-squared tests were performed to determine statistical significance (P<0.05).

Results

A total of 77 patients were included in the study, of which 21 (27%) qualified as acute phase PD and the remaining 56 (73%) as stable phase. Median duration of PD was 8 months for acute phase patients, and 21 months for stable phase (p=0.033). There was no significant difference in final change in curvature between the acute and stable phase of PD (16.2° vs. 14.9°, p=0.702). There was a significant difference in change in curvature reported after the first cycle of treatment between the acute and stable phase (21.7° vs. 12.5°, p=0.037). There was no statistically significant difference in frequency of TRAEs between the acute phase (3, 14%) and the stable phase (4, 7%) (p=0.332).

Conclusions

Although CCH is currently contraindicated during the acute phase of PD, preliminary results suggest that CCH use during this setting may be both effective and safe. There was no statistically significant difference in final change in curvature or TRAEs after CCH therapy between the acute and stable phase of PD.

Funding

None